Data from a Phase 2/3 trial shows etavopivat may reduce the incidence of vaso-occlusive crises and raise levels of hemoglobin ...
Sickle cell patients often face challenges when implementing their care plans. Columnist Mary Shaniqua describes what good ...
Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...
Invisible complications of sickle cell disease can result in a lack of understanding and proper care, says columnist.
The majority of SCD patients given Lyfgenia in clinical trials remained free of vaso-occlusive events (VOEs) following ...
It’s almost winter again here in the U.K., and every year I’m shocked by the cold weather and its impact on my body. Winter has always been one of my greatest adversaries, and as the seasons shift, ...
Kanglin Biotechnology has raised $20 million in financing to advance the development of sickle cell gene therapy KL003.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback